Medicamen Biotech vs Gennex Laboratories vs QMS Medical: Which Stock Should You Track

Medicamen Biotech vs Gennex Laboratories vs QMS Medical Allied Services starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.

All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.

Click Here – Get Free Investment Predictions

Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services: Company Overview

Medicamen Biotech is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 419 crore, a return on equity of 3.50% and a book value of Rs 196.82 per share. Its quarterly revenue moved from Rs 43.51 crore in June 2025 to Rs 48.76 crore in June 2026, a change of +12.1%.

Gennex Laboratories is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 237 crore, a return on equity of 8.29% and a book value of Rs 9.16 per share. Its quarterly revenue moved from Rs 36.46 crore in June 2025 to Rs 41.85 crore in June 2026, a change of +14.8%.

QMS Medical Allied Services is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 372 crore, a return on equity of 9.67% and a book value of Rs 53.88 per share. Its quarterly revenue moved from Rs 46.82 crore in June 2025 to Rs 57.29 crore in June 2026, a change of +22.4%.

Medicamen Biotech vs Gennex Laboratories vs QMS Medical Allied Services: Valuation and Profitability Snapshot

Metric	Medicamen Biotech	Gennex Laboratories	QMS Medical Allied Services
Market Cap (approx.)	Rs 419 crore	Rs 237 crore	Rs 372 crore
PE Ratio (TTM)	41.70	11.49	29.57
PB Ratio	1.57	1.07	3.57
Return on Equity (ROE)	3.50%	8.29%	9.67%
EPS (TTM, Rs)	7.40	0.85	6.51
Dividend Yield	0.32%	0.00%	2.60%
Debt to Equity	0.17	0.36	0.65
Book Value per Share (Rs)	196.82	9.16	53.88

Check the Univest Screener for Live Data

On valuation, Medicamen Biotech trades at a PE of 41.70 and a PB of 1.57, Gennex Laboratories at a PE of 11.49 and a PB of 1.07, while QMS Medical Allied Services trades at a PE of 29.57 and a PB of 3.57. On return on equity, the three post 3.50%, 8.29% and 9.67% respectively, and on dividend yield they stand at 0.32%, 0.00% and 2.60%. Medicamen Biotech has the highest market capitalisation of the three at Rs 419 crore, while Gennex Laboratories has the lowest at Rs 237 crore. Medicamen Biotech has the highest PE ratio of the three at 41.70, while Gennex Laboratories has the lowest at 11.49. QMS Medical Allied Services has the highest return on equity of the three at 9.67%, while Medicamen Biotech has the lowest at 3.50%. QMS Medical Allied Services has the highest debt to equity ratio of the three at 0.65, while Medicamen Biotech has the lowest at 0.17. Debt to equity is 0.17, 0.36 and 0.65 for the three respectively.

Medicamen Biotech vs Gennex Laboratories vs QMS Medical Allied Services: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)	YoY Change (Net Profit)
Medicamen Biotech	Rs 48.76 crore	Rs 1.85 crore	+12.1%	-21.8%	+15.6%
Gennex Laboratories	Rs 41.85 crore	Rs 4.67 crore	+14.8%	-32.8%	-7.0%
QMS Medical Allied Services	Rs 57.29 crore	Rs 3.96 crore	+22.4%	+28.3%	+25.3%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.

Medicamen Biotech vs Gennex Laboratories vs QMS Medical Allied Services: Five-Quarter Revenue and Net Profit Trend

The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Medicamen Biotech vs Gennex Laboratories vs QMS Medical Allied Services, which helps separate a one-quarter move from a steadier pattern.

Quarterly revenue (Rs crore)

Quarter	Medicamen Biotech	Gennex Laboratories	QMS Medical Allied Services
June 2025	Rs 43.51 crore	Rs 36.46 crore	Rs 46.82 crore
September 2025	Rs 47.54 crore	Rs 39.30 crore	Rs 44.92 crore
December 2025	Rs 47.44 crore	Rs 45.55 crore	Rs 37.56 crore
March 2026	Rs 62.39 crore	Rs 62.28 crore	Rs 44.64 crore
June 2026	Rs 48.76 crore	Rs 41.85 crore	Rs 57.29 crore

Quarterly net profit (Rs crore)

Quarter	Medicamen Biotech	Gennex Laboratories	QMS Medical Allied Services
June 2025	Rs 1.60 crore	Rs 5.02 crore	Rs 3.16 crore
September 2025	Rs 2.11 crore	Rs 5.51 crore	Rs 3.58 crore
December 2025	Rs 1.63 crore	Rs 5.99 crore	Rs 3.17 crore
March 2026	Rs 4.45 crore	Rs 4.46 crore	Rs 1.88 crore
June 2026	Rs 1.85 crore	Rs 4.67 crore	Rs 3.96 crore

Medicamen Biotech reported revenue of Rs 43.51 crore in June 2025 and Rs 48.76 crore in June 2026, a change of +12.1% across the period. Its highest quarterly revenue in this window was Rs 62.39 crore in March 2026. Net profit stood at Rs 1.85 crore in June 2026, which is a net profit margin of 3.79%.

Gennex Laboratories reported revenue of Rs 36.46 crore in June 2025 and Rs 41.85 crore in June 2026, a change of +14.8% across the period. Its highest quarterly revenue in this window was Rs 62.28 crore in March 2026. Net profit stood at Rs 4.67 crore in June 2026, which is a net profit margin of 11.16%.

QMS Medical Allied Services reported revenue of Rs 46.82 crore in June 2025 and Rs 57.29 crore in June 2026, a change of +22.4% across the period. Its highest quarterly revenue in this window was Rs 57.29 crore in June 2026. Net profit stood at Rs 3.96 crore in June 2026, which is a net profit margin of 6.91%.

Download the Univest iOS App or Univest Android App to track Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, order flow, raw material costs and the small revenue base that makes quarterly results swing. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.

It also helps to read the latest quarterly filings and investor presentations of Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.

Conclusion

Medicamen Biotech vs Gennex Laboratories vs QMS Medical Allied Services highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Medicamen Biotech vs Gennex Laboratories vs QMS Medical Allied Services

What is the market cap difference between Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services?

Ans. As of October 2026, Medicamen Biotech has a market cap of approximately Rs 419 crore, Gennex Laboratories is at approximately Rs 237 crore, and QMS Medical Allied Services is at approximately Rs 372 crore.

What are the PE and PB ratios of Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services?

Ans. As of October 2026, the PE ratios stand at 41.70, 11.49 and 29.57 respectively, and the price to book ratios stand at 1.57, 1.07 and 3.57 respectively.

Which of the three has the highest ROE?

Ans. Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services post ROE of 3.50%, 8.29% and 9.67% respectively as of October 2026. QMS Medical Allied Services has the highest return on equity of the three at 9.67%, while Medicamen Biotech has the lowest at 3.50%.

Which of these three stocks pays the highest dividend yield?

Ans. Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services carry dividend yields of 0.32%, 0.00% and 2.60% respectively.

What is the debt to equity ratio for Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services?

Ans. Medicamen Biotech carries a debt to equity of 0.17, Gennex Laboratories of 0.36, and QMS Medical Allied Services of 0.65.

What were the latest quarterly revenue and net profit of Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services?

Ans. For Q1 FY27 (quarter ended June 2026), Medicamen Biotech reported revenue of Rs 48.76 crore and net profit of Rs 1.85 crore, Gennex Laboratories reported revenue of Rs 41.85 crore and net profit of Rs 4.67 crore, and QMS Medical Allied Services reported revenue of Rs 57.29 crore and net profit of Rs 3.96 crore.

Does this comparison recommend one of Medicamen Biotech, Gennex Laboratories and QMS Medical Allied Services?

Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.